These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 21209285)
1. Concurrent allorecognition has a limited impact on posttransplant vaccination. Manzo T; Hess Michelini R; Basso V; Ricupito A; Chai JG; Simpson E; Bellone M; Mondino A J Immunol; 2011 Feb; 186(3):1361-8. PubMed ID: 21209285 [TBL] [Abstract][Full Text] [Related]
2. Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Hess Michelini R; Freschi M; Manzo T; Jachetti E; Degl'Innocenti E; Grioni M; Basso V; Bonini C; Simpson E; Mondino A; Bellone M Cancer Res; 2010 May; 70(9):3505-14. PubMed ID: 20388780 [TBL] [Abstract][Full Text] [Related]
3. Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation. Hess Michelini R; Manzo T; Sturmheit T; Basso V; Rocchi M; Freschi M; Listopad J; Blankenstein T; Bellone M; Mondino A Cancer Res; 2013 Aug; 73(15):4641-52. PubMed ID: 23749644 [TBL] [Abstract][Full Text] [Related]
4. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model. Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433 [TBL] [Abstract][Full Text] [Related]
5. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579 [TBL] [Abstract][Full Text] [Related]
6. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307 [TBL] [Abstract][Full Text] [Related]
7. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide. van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809 [TBL] [Abstract][Full Text] [Related]
8. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
9. Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone. Eljaafari A; Yuruker O; Ferrand C; Farre A; Addey C; Tartelin ML; Thomas X; Tiberghien P; Simpson E; Rigal D; Scott D J Immunol; 2013 Jan; 190(1):184-94. PubMed ID: 23225889 [TBL] [Abstract][Full Text] [Related]
10. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy. Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722 [TBL] [Abstract][Full Text] [Related]
11. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide. Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040 [TBL] [Abstract][Full Text] [Related]
12. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758 [TBL] [Abstract][Full Text] [Related]
13. Antigen-experienced CD4(+) T cells limit naïve T-cell priming in response to therapeutic vaccination in vivo. Schiering C; Guarnerio J; Basso V; Muzio L; Mondino A Cancer Res; 2010 Aug; 70(15):6161-70. PubMed ID: 20631073 [TBL] [Abstract][Full Text] [Related]
14. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice. Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200 [TBL] [Abstract][Full Text] [Related]
15. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer. Bristol JA; Schlom J; Abrams SI Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883 [TBL] [Abstract][Full Text] [Related]
16. Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses. Heine A; Grünebach F; Holderried T; Appel S; Weck MM; Dörfel D; Sinzger C; Brossart P Mol Ther; 2006 Feb; 13(2):280-8. PubMed ID: 16219490 [TBL] [Abstract][Full Text] [Related]
17. Langerin+ dermal dendritic cells are critical for CD8+ T cell activation and IgH γ-1 class switching in response to gene gun vaccines. Stoecklinger A; Eticha TD; Mesdaghi M; Kissenpfennig A; Malissen B; Thalhamer J; Hammerl P J Immunol; 2011 Feb; 186(3):1377-83. PubMed ID: 21187444 [TBL] [Abstract][Full Text] [Related]
18. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754 [TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
20. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma. Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]